Sex differences in cannabinoid 1 vs. cannabinoid 2 receptor-selective antagonism of antinociception produced by Δ 9- tetrahydrocannabinol and CP55,940 in the rat

Journal of Pharmacology and Experimental Therapeutics

Volumn 340, Issue 3, 2012, Pages 787-800

  Craft, Rebecca M ^a   Wakley, Alexa A ^a   Tsutsui, Kimberly T ^a   Laggart, Jillian D ^a  

^a WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; DRONABINOL; RIMONABANT;

ANIMAL EXPERIMENT; ANTINOCICEPTION; ARTICLE; CATALEPSY; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG BINDING; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; FEMALE; IN VIVO STUDY; LOCOMOTION; MALE; MOTOR ACTIVITY; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR AFFINITY; SEDATION; SEX DIFFERENCE;

ANALGESICS; ANIMALS; BORNANES; CYCLOHEXANOLS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; MALE; MORPHINE; MOTOR ACTIVITY; NALOXONE; PIPERIDINES; PYRAZOLES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; SEX CHARACTERISTICS; TETRAHYDROCANNABINOL;

EID: 84857335499     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.111.188540     Document Type: Article

References (41)

1. Agarwal N, Pacher P, Tegeder I, Amaya F, Constantin CE, Brenner GJ, Rubino T, Michalski CW, Marsicano G, Monory K, et al. (2007) Cannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptors. Nat Neurosci 10:870-879. (Pubitemid 47013432)
2. Anand P, Whiteside G, Fowler CJ, and Hohmann AG (2009) Targeting CB2 receptors and the endocannabinoid system for the treatment of pain. Brain Res Rev 60:255-266.
3. Borgen LA, Lott GC, and Davis WM (1973) Cannabis-induced hypothermia: a dose-effect comparison of crude marihuana extract and synthetic Δ9-tetrahydrocannabinol in male and female rats. Res Commun Chem Pathol Pharmacol 5:621-626.
4. Bradshaw HB, Rimmerman N, Krey JF, and Walker JM (2006) Sex and hormonal cycle differences in rat brain levels of pain-related cannabimimetic lipid mediators. Am J Physiol Regul Integr Comp Physiol 291:R349-R358. (Pubitemid 44035641)
5. Cohn RA, Barratt E, and Pirch JH (1972) Differences in behavioral responses of male and female rats to marijuana. 1. Proc Soc Exp Biol Med 140:1136-1139.
6. Craft RM and Leitl MD (2008) Gonadal hormone modulation of the behavioral effects of Δ9-tetrahydrocannabinol in male and female rats. Eur J Pharmacol 578:37-42. (Pubitemid 350179754)
7. Diaz S, Farhang B, Hoien J, Stahlman M, Adatia N, Cox JM, and Wagner EJ (2009) Sex differences in the cannabinoid modulation of appetite, body temperature and neurotransmission at POMC synapses. Neuroendocrinology 89:424-440.
8. Esfandyari T, Camilleri M, Ferber I, Burton D, Baxter K, and Zinsmeister AR (2006) Effect of a cannabinoid agonist on gastrointestinal transit and postprandial satiation in healthy human subjects: a randomized, placebo-controlled study. J Neurogastroenterol Motil 18:831-838. (Pubitemid 44201169)
9. Fattore L, Spano MS, Altea S, Angius F, Fadda P, and Fratta W (2007) Cannabinoid self-administration in rats: sex differences and the influence of ovarian function. Br J Pharmacol 152:795-804. (Pubitemid 350034986)
10. Gong JP, Onaivi ES, Ishiguro H, Liu QR, Tagliaferro PA, Brusco A, and Uhl GR (2006) Cannabinoid CB2 receptors: immunohistochemical localization in rat brain. Brain Res 1071:10-23. (Pubitemid 43255471)
11. 1 receptor mRNA and endocannabinoid levels in the anterior pituitary gland. Biochem Biophys Res Commun 270:260-266.
12. Govaerts SJ, Hermans E, and Lambert DM (2004) Comparison of cannabinoid ligands affinities and efficacies in murine tissues and in transfected cells expressing human recombinant cannabinoid receptors. Eur J Pharm Sci 23:233-243. (Pubitemid 39369878)
13. Gutierrez T, Farthing JN, Zvonok AM, Makriyannis A, and Hohmann AG (2007) Activation of peripheral cannabinoid CB1 and CB2 receptors suppresses the maintenance of inflammatory nociception: a comparative analysis. Br J Pharmacol 150:153-163. (Pubitemid 46160605)
14. Haney M (2007) Opioid antagonism of cannabinoid effects: differences between marijuana smokers and nonmarijuana smokers. Neuropsychopharmacology 32:1391-1403.
15. Hurtado FK, Ravanello A, Arend MZ, Wrasse M, Dalmora SL, and Rolim CM (2010) Validated stability-indicating RP-HPLC method for the determination of rimonabant in a pharmaceutical dosage form. J AOAC Int 93:869-875.
16. Institute of Laboratory Animal Resources (1996) Guide for the Care and Use of Laboratory Animals 7th ed. Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council, Washington, DC.
17. 57 -THC induced behavioral effects by rimonabant: time course studies in rats. Eur J Pharmacol 648:133-138.
18. Ko MC and Woods JH (1999) Local administration of Δ9- tetrahydrocannabinol attenuates capsaicin-induced thermal nociception in rhesus monkeys: a peripheral cannabinoid action. Psychopharmacology (Berl) 143:322-326.
19. 1 cannabinoid receptors be selectively targeted for therapeutic gain? Trends Pharmacol Sci 30:1-7.
20. Lichtman AH and Martin BR (1997) The selective cannabinoid antagonist SR 141716A blocks cannabinoid-induced antinociception in rats. Pharmacol Biochem Behav 57:7-12. (Pubitemid 27261386)
21. Mathew RJ, Wilson WH, and Davis R (2003) Postural syncope after marijuana: a transcranial Doppler study of the hemodynamics. Pharmacol Biochem Behav 75:309-318. (Pubitemid 36859816)
22. Negus SS, Burke TF, Medzihradsky F, and Woods JH (1993) Effects of opioid agonists selective for μ, κ and δ opioid receptors on schedule-controlled respondingin rhesus monkeys: antagonism by quadazocine. J Pharmacol Exp Ther 267:896-903.
23. Onaivi ES, Chaudhuri G, Abaci AS, Parker M, Manier DH, Martin PR, and HubbardJR (1999) Expression of cannabinoid receptors and their gene transcripts inhuman blood cells. Prog Neuropsychopharmacol Biol Psychiatry 23:1063-1077.
24. Pertwee RG (2008) Ligands that target cannabinoid receptors in the brain: from THCto anandamide and beyond. Addict Biol 13:147-159.
25. Riebe CJ, Hill MN, Lee TT, Hillard CJ, and Gorzalka BB (2010) Estrogenic regulationof limbic cannabinoid receptor binding. Psychoneuroendocrinology 35:1265-1269.
26. Rinaldi-Carmona M, Pialot F, Congy C, Redon E, Barth F, Bachy A, Brelière JC, Soubrié P, and Le Fur G (1996) Characterization and distribution of binding sitesfor [3H]-SR 141716A, a selective brain (CB1) cannabinoid receptor antagonist, inrodent brain. Life Sci 58:1239-1247.
27. Rodríguez de Fonseca F, Cebeira M, Ramos JA, Martín M, and Fernández-Ruiz JJ (1994) Cannabinoid receptors in rat brain areas: sexual differences, fluctuationsduring estrous cycle and changes after gonadectomy and sex steroid replacement. Life Sci 54:159-170.
28. Romero EM, Fernández B, Sagredo O, Gomez N, Urigüen L, Guaza C, De Miguel R, Ramos JA, and Viveros MP (2002) Antinociceptive, behavioural and neuroendocrineeffects of CP 55,940 in young rats. Brain Res Dev Brain Res 136:85-92. (Pubitemid 34718114)
29. Romero-Sandoval A and Eisenach JC (2007) Spinal cannabinoid receptor type 2 activation reduces hypersensitivity and spinal cord glial activation after pawincision. Anesthesiology 106:787-794. (Pubitemid 46555623)
30. Rowlett JK and Woolverton WL (1996) Assessment of benzodiazepine receptor heterogeneity in vivo: apparent pA2 and pKB analyses from behavioral studies. Psychopharmacology (Berl) 128:1-16. (Pubitemid 26379260)
31. Russo EB (2008) Cannabinoids in the management of difficult to treat pain. Ther Clin Risk Manag 4:245-259.
32. Ryberg E, Larsson N, Sjögren S, Hjorth S, Hermansson NO, Leonova J, Elebring T, Nilsson K, Drmota T, and Greasley PJ (2007) The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol 152:1092-1101. (Pubitemid 350166046)
33. Shire D, Calandra B, Bouaboula M, Barth F, Rinaldi-Carmona M, Casellas P, and Ferrara P (1999) Cannabinoid receptor interactions with the antagonists SR 141716A and SR 144528. Life Sci 65:627-635. (Pubitemid 29362768)
34. Tseng AH and Craft RM (2001) Sex differences in antinociceptive and motoric effects of cannabinoids. Eur J Pharmacol 430:41-47. (Pubitemid 33042709)
35. Tseng AH and Craft RM (2004) CB1 receptor mediation of cannabinoid behavioral effects in male and female rats. Psychopharmacology 172:25-30. (Pubitemid 38299747)
36. Tseng AH, Harding JW, and Craft RM (2004) Pharmacokinetic factors in sex differences in Δ9-tetrahydrocannabinol-induced behavioral effects in rats. Behav Brain Res 154:77-83. (Pubitemid 39070455)
37. Varvel SA, Bridgen DT, Tao Q, Thomas BF, Martin BR, and Lichtman AH (2005) Δ9-Tetrahydrocannbinol accounts for the antinociceptive, hypothermic, and cataleptic effects of marijuana in mice. J Pharmacol Exp Ther 314:329-337. (Pubitemid 41058270)
38. Wakley AA and Craft RM (2011) Antinociception and sedation following intracerebroventricular administration of Δ9-tetrahydrocannabinol in female vs. male rats. Behav Brain Res 216:200-206.
39. Wiley JL and Evans RL (2009) To breed or not to breed? Empirical evaluation of drug effects in adolescent rats. Int J Dev Neurosci 27:9-20.
40. 9-tetrahydrocannabinol in adolescent and adult rats. J Pharmacol Exp Ther 320:1097-1105.
41. Yu XH, Cao CQ, Martino G, Puma C, Morinville A, St-Onge S, Lessard E, Perkins MN, and Laird JM (2010) A peripherally restricted cannabinoid receptor agonist produces robust anti-nociceptive effects in rodent models of inflammatory and neuropathic pain. Pain 151:337-344.